Why the study?
Pediatric idiopathic pulmonary arterial hypertension refractory to maximal medical therapy is associated with high morbidity and mortality, and therapeutic options remain limited.
Does sotatercept improve clinical and hemodynamic outcomes in pediatric patients with end-stage idiopathic pulmonary arterial hypertension refractory to conventional therapy?
Population
A 12-year-old girl with end-stage IPAH and acute decompensated right heart failure
Comparison
Compassionate-use sotatercept
Design
Case report
Key result
Sotatercept rescue therapy led to rapid clinical recovery, improving WHO functional class from IV to II and normalizing NT-proBNP levels in a 12-year-old girl with refractory end-stage IPAH.
Authors
Loading...
May serve as rescue therapy in refractory pediatric IPAH; leaves open efficacy pending larger dedicated trials.
Does sotatercept improve clinical and hemodynamic outcomes in pediatric patients with end-stage idiopathic pulmonary arterial hypertension refractory to conventional therapy?
Sotatercept may serve as an effective, life-saving rescue therapy for pediatric patients with severe, refractory idiopathic pulmonary arterial hypertension.
Pelczar‐Płachta et al. (2026) studied this question. Sotatercept rescue therapy led to rapid clinical recovery, improving WHO functional class from IV to II and normalizing NT-proBNP levels in a 12-year-old girl with refractory end-stage IPAH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: